Apitope taps development director

Apitope International named Dr. Graham Roberts as development director for therapeutics.

Chimerix announced that Kenneth I. Moch has joined the company as chief operating officer.

Ore Pharmaceuticals has appointed Benjamin Palleiko as its new senior vice president and CFO.

Immucor announced that Geoffrey S. Crouse has been named vice president and COO.

Cellular Dynamics International has named Junying Yu, Ph.D., as senior research fellow at the company.

iCo Therapeutics named Donald N. Buell, M.D., to chair the Scientific Advisory Board committee overseeing the development of iCo-009.

Regado Biosciences has expanded its Medical Advisory Board. Three new members, Dr. John Eikelboom of Canada, Dr. Philippe Menasche of France and Dr. Lars Wallentin of Sweden, join the original members.

Bob Linke was named president and CEO of Embera NeuroTherapeutics earlier this year. Dr. Bruce McCarthy recently joined as Embera's consultant Chief Medical Officer and Vice President of Clinical Development. Dr. Carol Gloff has also joined the company as a pharmaceutical regulatory consultant

Burrill & Company announced that Joao Paulo V. Poiares Baptista has joined the firm as managing director for both Burrill & Company and Burrill Latin America.

NeurogesX, announced that Bruce A. Peacock has resigned from his roles as Audit Committee chairman and director to focus on his responsibilities as CEO of privately-held Alba Therapeutics.

InNexus Biotechnology announced the addition of noted clinical oncologist and cancer research pioneer Daniel Von Hoff, M.D., to the InNexus Scientific Advisory Board.

NeoStem has entered into an advisory consulting agreement with Dr. Cai Jianqian of the Shandong Provincial Association of Chinese Medicine to assist the company with its expansion into China and facilitate collaborations with prestigious hospitals in the Peoples Republic of China.

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.